Lack of association between the FAS/FASL polymorphisms and cervical cancer risk: A meta‑analysis

Du,Yingying; Hu,Lixia; Pan,Yueyin

doi:10.3892/br.2013.56

Lack of association between the FAS/FASL polymorphisms and cervical cancer risk: A meta‑analysis

Authors:
- Yingying Du
- Lixia Hu
- Yueyin Pan
View Affiliations

Affiliations: Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China
Published online on: January 17, 2013 https://doi.org/10.3892/br.2013.56
Pages: 269-274

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

FAS/FASL gene promoter polymorphisms are associated with cervical cancer risk, however, results from previous studies have been conflicting. To obtain a more precise estimation of the association between these polymorphisms and cancer risk, a meta‑analysis was performed. All eligible studies up to November 1st, 2012, concerning FAS‑670 A/G, FAS‑1377 G/A and FASL‑844 T/C polymorphisms and cervical cancer risk, were collected from the following electronic databases: PubMed, Excerpta Medica Database and Chinese Biomedical Literature Database. The odds ratio (OR) and 95% confidence interval (95% CI) were used to assess the strength of the association via the additive, codominant, dominant and recessive models. In total, 10 publications with 11 case‑control studies (10 on FAS‑670 A/G, 5 on FAS‑1377 G/A and 6 on FASL‑844 T/C polymorphisms) were included in this meta‑analysis. No association between FAS‑670 A/G, FAS‑1377 G/A and FASL‑844 T/C polymorphisms and cervical cancer susceptibility for all the genetic models was identified. Following stratification of the studies by ethnicity or source of controls, similar results were obtained. In conclusion, our findings showed that the FAS‑670 A/G, FAS‑1377 G/A and FASL‑844 T/C polymorphisms are not associated with cervical cancer risk. Future studies with larger sample sizes are required to further evaluate these associations.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Wallin KL, Wiklund F, Luostarinen T, et al: A population-based prospective study of Chlamydia trachomatis infection and cervical carcinoma. Int J Cancer. 101:371–374. 2002. View Article : Google Scholar : PubMed/NCBI
3	Schiffman M, Castle PE, Jeronimo J, Rodriguez AC and Wacholder S: Human papillomavirus and cervical cancer. Lancet. 370:890–907. 2007. View Article : Google Scholar : PubMed/NCBI
4	zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2:342–350. 2002.PubMed/NCBI
5	Andera L: Signaling activated by the death receptors of the TNFR family. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 153:173–180. 2009. View Article : Google Scholar : PubMed/NCBI
6	Kim R, Emi M, Tanabe K, Uchida Y and Toge T: The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer. 100:2281–2291. 2004. View Article : Google Scholar : PubMed/NCBI
7	Suda T, Takahashi T, Golstein P and Nagata S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 75:1169–1178. 1993. View Article : Google Scholar : PubMed/NCBI
8	Huang QR, Morris D and Manolios N: Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol. 34:577–582. 1997. View Article : Google Scholar : PubMed/NCBI
9	Sibley K, Rollinson S, Allan JM, et al: Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res. 63:4327–4330. 2003.PubMed/NCBI
10	Wu J, Metz C, Xu X, et al: A novel polymorphic CAAT/enhancer- binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol. 170:132–138. 2003. View Article : Google Scholar
11	Sun T, Zhou Y, Li H, et al: FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med. 202:967–974. 2005. View Article : Google Scholar : PubMed/NCBI
12	Lai HC, Lin WY, Lin YW, et al: Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: an analysis of haplotype and gene-gene interaction. Gynecol Oncol. 99:113–118. 2005. View Article : Google Scholar : PubMed/NCBI
13	Zoodsma M, Nolte IM, Schipper M, et al: Interleukin-10 and Fas polymorphisms and susceptibility for (pre)neoplastic cervical disease. Int J Gynecol Cancer. 15(Suppl 3): 282–290. 2005. View Article : Google Scholar : PubMed/NCBI
14	Ueda M, Terai Y, Kanda K, et al: Fas gene promoter -670 polymorphism in gynecological cancer. Int J Gynecol Cancer. 16(Suppl 1): 179–182. 2006. View Article : Google Scholar : PubMed/NCBI
15	Kang S, Dong SM, Seo SS, Kim JW and Park SY: FAS-1377 G/A polymorphism and the risk of lymph node metastasis in cervical cancer. Cancer Genet Cytogenet. 180:1–5. 2008. View Article : Google Scholar : PubMed/NCBI
16	Zucchi F, da Silva ID, Ribalta JC, et al: Fas/CD95 promoter polymorphism gene and its relationship with cervical carcinoma. Eur J Gynaecol Oncol. 30:142–144. 2009.PubMed/NCBI
17	Kordi Tamandani DM, Sobti RC and Shekari M: Association of Fas-670 gene polymorphism with risk of cervical cancer in North Indian population. Clin Exp Obstet Gynecol. 35:183–186. 2008.
18	Chatterjee K, Engelmark M, Gyllensten U, et al: Fas and FasL gene polymorphisms are not associated with cervical cancer but differ among Black and Mixed-ancestry South Africans. BMC Research Notes. 2:2382009. View Article : Google Scholar : PubMed/NCBI
19	Ivansson EL, Gustavsson IM, Magnusson JJ, et al: Variants of chemokine receptor 2 and interleukin 4 receptor, but not inter-leukin 10 or Fas ligand, increase risk of cervical cancer. Int J Cancer. 121:2451–2457. 2007. View Article : Google Scholar : PubMed/NCBI
20	Ueda M, Hung YC, Terai Y, et al: Fas gene promoter -670 polymorphism (A/G) is associated with cervical carcinogenesis. Gynecol Oncol. 98:129–133. 2005. View Article : Google Scholar : PubMed/NCBI
21	Engelmark MT, Renkema KY and Gyllensten UB: No evidence of the involvement of the Fas-670 promoter polymorphism in cervical cancer in situ. Int J Cancer. 112:1084–1085. 2004. View Article : Google Scholar : PubMed/NCBI
22	Chen YQ, Lu LG, Tian QF, et al: The research of Fas-670 polymorphism and cervical cancer susceptibility. Natl Med J China. 86:2792–2794. 2006.
23	DerSimonian R and Laird N: Meta-analysis in clinical trials. Control Clin Trials. 7:177–188. 1986. View Article : Google Scholar : PubMed/NCBI
24	Mantel N and Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 22:719–748. 1959.PubMed/NCBI
25	Haber M: Exact significance levels of goodness-of-fit tests for the Hardy-Weinberg equilibrium. Hum Hered. 31:161–166. 1981. View Article : Google Scholar : PubMed/NCBI
26	Begg CB and Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics. 50:1088–1101. 1994. View Article : Google Scholar : PubMed/NCBI
27	Egger M, Davey Smith G, Schneider M and Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
28	Reed JC: Mechanisms of apoptosis. Am J Pathol. 157:1415–1430. 2000. View Article : Google Scholar
29	Qiu LX, Shi J, Yuan H, et al: FAS -1,377 G/A polymorphism is associated with cancer susceptibility: evidence from 10,564 cases and 12,075 controls. Hum Gen. 125:431–435. 2009. View Article : Google Scholar : PubMed/NCBI
30	Liu Y, Wen Q-J, Yin Y, et al: FASLG polymorphism is associated with cancer risk. Eur J Cancer. 45:2574–2578. 2009. View Article : Google Scholar : PubMed/NCBI